Interferon trials in small cell lung cancer at one institution: a comparison of results obtained before and after initiation of systematic treatment trials using IFN-alpha in combination with other modalities

Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
T M Ruotsalainen, K Mattson

Abstract

Chemotherapy became the primary treatment for small cell lung cancer (SCLC) in the early 1970s. The standard drug combinations were first vincristine, adriamycin, and cyclophosphamide (VAC) and then, from the early 1980s, etoposide-platinum combinations. Despite a good initial objective response, however, patients usually suffer a rapid relapse. Treatment development has, therefore, focused on ways to overcome drug resistance, and on the addition of cytokines to the chemotherapeutic arsenal. Interferon (IFN) was one of the first cytokines found to have anticancer effects, and it was introduced into the combined modality regimens used to treat SCLC in the early 1980s in an attempt to overcome the problem of early relapse. The role of IFN was investigated with the aim of establishing how best to combine it with other treatments for SCLC. In this paper, we review the impact of IFN on the outcome for 714 SCLC patients who were treated in randomized IFN trials at one institution over a period of 20 years and IFN trials conducted at other institutions during the same period. The parameters we used at our institution to measure outcome tended to improve during the period when patients were being treated in our three randomized IFN tri...Continue Reading

References

Jan 1, 1978·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·H StranderG Söderberg
Jun 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P Warde, D Payne
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K MattsonK Cantell
Nov 12, 1992·The New England Journal of Medicine·D C Ihde
Jan 23, 1987·Science·J Folkman, M Klagsbrun
Jan 1, 1987·Nouvelle Revue Française D'hématologie·A Camez, G Tobelem
Aug 8, 1987·Lancet·F R Balkwill, J F Smyth
Aug 1, 1987·International Journal of Radiation Oncology, Biology, Physics·L R HolstiK Cantell
Mar 1, 1983·British Journal of Cancer·D H JonesA K Dixon
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R JettJ B Gerstner
May 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S TomaR Rosso
Dec 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K KellyS Rivkin
Sep 1, 1996·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·K ZarogoulidisC Vamvalis
Feb 1, 1997·The European Respiratory Journal·C PriorH Huber
Feb 1, 1997·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·K MattsonK Cantell
Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·N van ZandwijkG Giaccone
Jul 8, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M L Janssen-HeijnenJ W Coebergh
Sep 11, 1998·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·U N LassenP Dombernowsky
Apr 1, 1999·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·M HalmeK Mattson
Apr 23, 1999·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·T M RuotsalainenK Mattson
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P ChuteB E Johnson

❮ Previous
Next ❯

Citations

Jan 1, 2013·Lung Cancer Management·Matthew Whitehurst, Alberto Chiappori
Aug 9, 2020·Frontiers in Oncology·Andreas SaltosAlberto Chiappori
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·SaeHeum SongJessie L-S Au

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.